Compare Divis Laboratories with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PROCTER & GAMBLE HEALTH - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PROCTER & GAMBLE HEALTH DIVIS LABORATORIES/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 49.9 18.0 277.5% View Chart
P/BV x 13.4 7.2 184.3% View Chart
Dividend Yield % 0.5 6.5 7.0%  

Financials

 DIVIS LABORATORIES   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
DIVIS LABORATORIES/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,6393,549 46.2%   
Low Rs1,1151,301 85.7%   
Sales per share (Unadj.) Rs186.3511.4 36.4%  
Earnings per share (Unadj.) Rs51.061.3 83.1%  
Cash flow per share (Unadj.) Rs57.374.0 77.4%  
Dividends per share (Unadj.) Rs16.00440.00 3.6%  
Dividend yield (eoy) %1.218.1 6.4%  
Book value per share (Unadj.) Rs261.8927.8 28.2%  
Shares outstanding (eoy) m265.4716.60 1,599.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.44.7 155.9%   
Avg P/E ratio x27.039.6 68.3%  
P/CF ratio (eoy) x24.032.8 73.3%  
Price / Book Value ratio x5.32.6 201.3%  
Dividend payout %31.4717.9 4.4%   
Avg Mkt Cap Rs m365,59240,257 908.1%   
No. of employees `00011.81.1 1,044.7%   
Total wages/salary Rs m5,4231,313 413.1%   
Avg. sales/employee Rs Th4,175.17,486.7 55.8%   
Avg. wages/employee Rs Th457.71,157.6 39.5%   
Avg. net profit/employee Rs Th1,141.8897.2 127.3%   
INCOME DATA
Net Sales Rs m49,4638,490 582.6%  
Other income Rs m1,556244 638.1%   
Total revenues Rs m51,0198,734 584.2%   
Gross profit Rs m18,7181,482 1,263.4%  
Depreciation Rs m1,689211 799.7%   
Interest Rs m350-   
Profit before tax Rs m18,5511,514 1,225.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m5,023563 893.0%   
Profit after tax Rs m13,5271,017 1,329.6%  
Gross profit margin %37.817.5 216.9%  
Effective tax rate %27.137.1 72.9%   
Net profit margin %27.312.0 228.2%  
BALANCE SHEET DATA
Current assets Rs m46,50115,343 303.1%   
Current liabilities Rs m8,4681,960 432.0%   
Net working cap to sales %76.9157.6 48.8%  
Current ratio x5.57.8 70.2%  
Inventory Days Days13149 268.4%  
Debtors Days Days8628 301.8%  
Net fixed assets Rs m25,7971,209 2,133.2%   
Share capital Rs m531166 319.8%   
"Free" reserves Rs m68,96215,235 452.7%   
Net worth Rs m69,49315,401 451.2%   
Long term debt Rs m00-   
Total assets Rs m80,38317,595 456.9%  
Interest coverage x531.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.60.5 127.5%   
Return on assets %16.95.8 291.8%  
Return on equity %19.56.6 294.7%  
Return on capital %26.710.3 260.7%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2381,636 2,520.2%   
Fx outflow Rs m12,4054,368 284.0%   
Net fx Rs m28,833-2,732 -1,055.4%   
CASH FLOW
From Operations Rs m9,543-1,304 -731.9%  
From Investments Rs m-6,85412,697 -54.0%  
From Financial Activity Rs m-2,459-301 818.4%  
Net Cashflow Rs m23011,093 2.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 11.8 18.2 64.8%  
FIIs % 19.0 1.0 1,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 29.1 59.1%  
Shareholders   31,796 28,591 111.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Mar 5, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS